GlaxoSmithKline Pharmaceuticals informs about outcome of board meeting

02 Mar 2026 Evaluate
In compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), GlaxoSmithKline Pharmaceuticals has informed that the Board of Directors at its meeting held today have approved the appointment Ronojit Biswas (DIN 07684843) as the Whole-Time Director & Chief Financial Officer (CFO) of the Company for term of three years with effect from 1st April 2026 & Juby Chandy (Current CFO) to transition into a new role in GSK Group. Ronojit Biswas is not related to any of the existing Directors of the Company, and he is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority. The Meeting of Board of Directors commenced at 11.00 am and concluded at 12.00 noon.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2512.75 34.65 (1.40%)
06-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.95
Dr. Reddys Lab 1303.90
Cipla 1321.75
Zydus Lifesciences 912.95
Lupin 2344.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×